SCHEMBL43169

SCHEMBL43169

NC(=O)N1CCc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.68
TSHR P16473 4/20 0.66
ALDH1A1 P00352 5/20 0.64
HPGD P15428 2/20 0.64
KMT2A Q03164 2/20 0.62
MEN1 O00255 1/20 0.62
MAPT P10636 1/20 0.62
SIGMAR1 Q99720 1/20 0.61
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.58
LMNA P02545 2/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
NFKB1 P19838 1/20 0.58
NFKB2 Q00653 1/20 0.58
RELA Q04206 1/20 0.58
GAA P10253 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29443491 1.00 NOTUM (0.68) NOTUMTSHRALDH1A1HPGDKMT2A
Hydrochloric Acid SCHEMBL5573069 0.98 NOTUM (0.66) NOTUMTSHRALDH1A1HPGDKMT2A
Hydrochloric Acid SCHEMBL29858239 0.98 NOTUM (0.66) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL29640094 0.89 SMN1; SMN2 (0.74) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL3120560 0.89 SMN1; SMN2 (0.74) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL4865076 0.87 SMN1; SMN2 (0.67) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL14608503 0.85 SMN1; SMN2 (0.64) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL29804966 0.84 NOTUM (0.72) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL5492978 0.84 SMN1; SMN2 (0.79) NOTUMTSHRALDH1A1HPGDKMT2A
SCHEMBL17117378 0.84 NOTUM (0.72) NOTUMTSHRALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301736-B1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2025-10-08 EP claimed
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS QLi5 Therapeutics AG (DE) 2024-12-19 US claimed
CN-105518005-B Tricyclic pyridine-carboxamide derivatives as ROCK inhibitors 百时美施贵宝公司 2018-07-20 CN claimed
CN-105073741-B Phthalazinones and isoquinolinones as ROCK inhibitors 百时美施贵宝公司 2017-08-08 CN claimed
CN-104540806-B Azaheterocycles as BIR2 and/or BIR3 inhibitors 霍夫曼-拉罗奇有限公司 2017-05-03 CN claimed
EP-2128258-B1 NOVEL AMIDASE, GENE FOR THE SAME, VECTOR, TRANSFORMANT, AND METHOD FOR PRODUCTION OF OPTICALLY ACTIVE CARBOXYLIC ACID AMIDE AND OPTICALLY ACTIVE CARBOXYLIC ACID BY USING ANY ONE OF THOSE ITEMS KANEKA CORP (JP) 2013-09-11 EP claimed
US-20130059348-A1 NOVEL AMIDASE, GENE FOR THE SAME, VECTOR, TRANSFORMANT, AND METHOD FOR PRODUCTION OF OPTICALLY ACTIVE CARBOXYLIC ACID AMIDE AND OPTICALLY ACTIVE CARBOXYLIC ACID BY USING ANY ONE OF THOSE ITEMS KANEKA CORPORATION (JP) 2013-03-07 US claimed
CN-102725292-A Imidazopyridine compounds as novel constructs for multi-target kinase inhibition ABBOTT LAB 2012-10-10 CN claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
EP-2493853-A1 ORGANIC COMPOUNDS Givaudan SA (CH) 2012-09-05 EP claimed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO claimed
US-6593344-B1 These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum and autoimmune diseases KLINGE PHARMA GMBH (DE) 2003-07-15 US claimed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP claimed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 US claimed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US claimed
US-6274594-B1 ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; SMITHKLINE BEECHAM P.L.C. (GB) 2001-08-14 US claimed
EP-1032570-A1 ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE SMITHKLINE BEECHAM PLC (GB) 2000-09-06 EP claimed
WO-1999025709-A1 ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE SMITHKLINE BEECHAM P.L.C. (GB) 1999-05-27 WO claimed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 EP claimed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 NOTUM 2933/4885TSHR 916/4885ALDH1A1 339/4885
US-20240415819-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS PSMB5, PSMA5, PSMB1 NOTUM 1110/4885TSHR 4030/4885ALDH1A1 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.